ARTHEx Biotech — Series B · $87M

ARTHEx Biotech announced it had upsized its Series B to $87M total with new investor Bpifrance (via its Large Venture and InnoBio funds) leading the extension; the size of the new tranche alone was not disclosed, and the round builds on the Series B first closed in 2023. Proceeds advance ATX-01, an anti-miR therapy for myotonic dystrophy type 1 now in the Phase I/IIa ArthemiR trial, and expand its targeted RNA medicines pipeline.